HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform.

See the rest here:
Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *